Recent advancements in monoclonal antibody engineering are reshaping disease treatment, focusing on safety, effectiveness, and addressing current medical needs.

In a review paper published in Molecular Biomedicine, an international team of scientists comprehensively: (1) highlight the fundamentals of mAbs-development and optimization technologies, (2) focus ...

Scientists from the University of Sharjah think monoclonal antibodies hold the potential to be a far better treatment for ...

Explore how mAbs are transforming disease treatment, the evolution from murine to humanized antibodies, and the impact of biosimilar antibodies on cost-effective therapies.

It is essential to increase the number of autonomous agents in bioprocess development for biopharma innovation.

Identifying reliable operational parameters as early as possible in the development process can significantly streamline ...

The global upstream bioprocessing equipment market was valued at approximately US$ 7.75 billion in 2022 and is expected to ...

The FDA has approved a new presentation of Alvotech and Teva’s SELARSDI, for the treatment of ulcerative colitis and Crohn's ...

R&D software developer Dotmatics is rolling out a platform for discovering and developing therapeutic antibodies and proteins ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and ...

This study is led by Dr. Hassan Aboul-Ella (Department of Microbiology, Faculty of Veterinary Medicine, Cairo University).